Marc Ullman was quoted in a NutraIngredients-USA article, “NDI filings coming in at expected rate, FDA says, but questions on GRAS process remain.” The article focuses on the FDA’s belief that there will not be a significant change in how many companies are choosing to go through the process to file NDIs.

“I have been

Jeff Kaiser was interviewed for the Healthcare Risk Management Magazine article, “Coding Issues Carry Major Liability, Compliance Risks.” He discusses some of the major areas of coding risks for hospitals. He also explains the important role fraud reporting plays in a coding compliance program.

To read the article, click here.

Marc Ullman was quoted in a NutraIngredients-USA article, “FDA says Gottlieb statement does not signal CBD enforcement shift, but some questions unanswered, observers say.”

A statement by FDA Commissioner Dr. Scott Gottlieb noted that the US Food and Drug Administration has approved the first CBD drug, which was developed by English company GW Pharmaceuticals. The

Marc Ullman will be a speaker at the Vitafoods Asia at the Sands Expo & Convention Centre at Marina Bay Sands, Singapore in September 2018. Marc’s topic is “Bringing Your New Dietary Ingredient to the US Market May Be Easier Than You Think (But Maybe Not).”

Program Descriptive;

• Understanding whether you have a new

Jeff Kaiser provided his perspective for the article, “Attys Reflect On Escobar’s Impact 2 Years Later.”

According to Jeff, “While there is general agreement that Escobar intended a holistic approach in deciding materiality, interesting issues have arisen regarding what types of evidence are relevant in making this determination. For instance, is the government’s decision to decline

Rivkin Radler secured a victory in the first appellate case to interpret Insurance Law § 3408(c) since a 2014 amendment.

Under § 3408(c), a property insurer or an insured can demand that appraisers selected by the parties decide disagreements over the amount of the loss. Typically, insurers argue that an appraisal is confined to an

Marc Ullman was quoted in a NutrIngredients-USA article, “Some Shady Ingredients Find Home in Nootropics Category.” The article focuses on the fairly new dietary supplement topic, “nootropics” otherwise characterized as “smart drugs.”

Ullman says, “I think there is a stigma associated with nootropics. A lot of these ingredients are really old drugs that have been

On Wednesday, June 20, 2018, Marc Ullman will speak on a panel at the American Conference Institute’s 6th Annual Legal, Regulatory and Compliance Forum on Dietary Supplements.

Entitled, “Coattail Claims: The Latest Influx of Class Action Litigation Impacting Dietary Supplements,” the discussion will cover:

• Recent class action filings against dietary supplement manufacturers
• Strategies to

Marc Ullman was quoted in a Natural Products Insider article entitled, “CO Hemp Food Bill Passed by Legislature Seeks to Pre-Empt Pharma Lawsuits.” The article addresses a proposed bill in Colorado that will codify into law an existing policy to regulate hemp as a food ingredient.

Click here to read the article.

Marc Ullman was quoted in a Natural Products Insider article entitled, “FDA Triggered Industry Shift from ‘CBD’ to ‘Hemp Extracts’ in Dietary Supplements.” The article addresses the point that amid the escalating demands for CBD in the United States, many companies are selling “hemp extracts,” a strategy based on regulatory and scientific considerations.”

“If you’re